PCH Orkambi Roll-out Information

PCH Orkambi Roll-out

The CF team at Perth Children’s Hospital have provided us with the following statement regarding the rollout of Orkambi:

Dear CF families,

Many of you will be aware that the Pharmaceutical Benefits Advisory Committee has approved access to Orkambi (ivacaftor/lumacaftor) for CF patients six years and over who are homozygous for (have two copies of) the F508del gene mutation. While Orkambi will not substitute routine CF care, its use has been shown to reduce lung function decline over time in specific patients.

At this stage there has been no confirmation of when Orkambi will be available for prescription and details about the drug roll-out has not yet been released. Our team is working to get everything in place so that we will be able to assist those children and families that are eligible as soon as Orkambi is available.

While this is good news for the CF community we are very aware that not all our families will benefit from Orkambi. Fortunately many new therapies are in the production pipeline that we hope will soon be added to current treatment options.

The CF Multi-Disciplinary Team
Perth Children’s Hospital

For more information about Orkambi click here. We will update on this process as soon as we have more information.


For media enquiries please contact our Business Development Manager


Sign up for our newsletter!

2019 © Cystic Fibrosis Western Australia Privacy Policy | Refund & Delivery Policy | ABN: 19 156 339 182